Context: Congenital hyperinsulinism (CHI) has two main histological types: diffuse and focal. Heterozygous paternally inherited ABCC8/KCNJ11 mutations (depending upon whether recessive or dominant acting and occurrence of somatic maternal allele loss) can give rise to either phenotype. However, the relative proportion of these two phenotypes in a large cohort of CHI patients due to paternally inherited heterozygous ABCC8/KCNJ11 mutations has not been reported. Objective: The purpose of this study is to highlight the variable clinical phenotype and to characterise the distribution of diffuse and focal disease in a large cohort of CHI patients due to paternally inherited heterozygous ABCC8/KCNJ11 mutations. Design: A retrospective chart review of the CHI patients due to heterozygous paternally inherited ABCC8/KCNJ11 mutations from 2000 to 2013 was conducted. Results: Paternally inherited heterozygous ABCC8/KCNJ11 mutations were identified in 53 CHI patients. Of these, 18 (34%) either responded to diazoxide or resolved spontaneously. Fluorine-18 L-3, 4-dihydroxyphenylalanine positron emission tomography computerised tomography ( 18 F DOPA-PET CT) scanning in 3/18 children showed diffuse disease. The remaining 35 (66%) diazoxide-unresponsive children either had pancreatic venous sampling (nZ8) or 18
Introduction
Congenital hyperinsulinism (CHI) is one of the main causes of hypoglycaemia and is characterised by inappropriate insulin secretion (1) . Mutations in nine different genes (ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1, subunits: Kir6.2 encoded by KCNJ11 and SUR1 encoded by ABCC8 gene (2) . Both genes are localised in the 11p15.1 region and mutations in these accounts for the majority of CHI patients (3, 4, 5, 6, 7, 8, 9, 10, 11) .
There are two main forms of CHI (focal and diffuse) that are clinically identical but differ in histology, underlying genetic mechanism and management. In diffuse CHI, histologically there is an increase in the b-cell nuclear size throughout the pancreas. Diffuse CHI is genetically heterogeneous and most commonly due to mutations in ABCC8 or KCNJ11 genes (3, 12, 13, 14, 15) . Diazoxide, an agonist that targets the SUR1 subunit, is usually ineffective in patients with autosomal recessive form of ABCC8 or KCNJ11 mutations. The management of the medically unresponsive diffuse CHI patients involves near-total pancreatectomy.
The focal lesions are characterised by nodular hyperplasia of islet-like cell clusters with ductuloinsular complexes and scattered giant b-cell nuclei with normal surrounding tissue (16) . The focal CHI results from a paternally inherited heterozygous ABCC8/KCNJ11 mutation together with a somatic loss of the maternal chromosome in the 11p15 region (most likely caused by paternal isodisomy) (16, 17) . The resulting loss of heterozygosity (LOH) renders the b-cells biallelic for the abnormal foci, altering the K ATP channel and resulting in dysregulated insulin secretion within the focal lesion (16, 17, 18) . The consequent imbalance in the expression of adjacent imprinted genes implicated in cell proliferation (such as CDKN1C and H19 normally expressed from the maternal allele and IGF2 paternally expressed) within the 11p15.5 region leads to focal islet cell adenomatous hyperplasia (19, 20, 21, 22) . Focal CHI is usually medically unresponsive, although diazoxide-responsive focal CHI has been recently described (23) . Targeted surgical removal of the lesion will cure the patient.
Fluorine-18 L-3, 4-dihydroxyphenylalanine positron emission tomography computerised tomography ( 18 F DOPA-PET CT) scan can help to differentiate the focal from diffuse forms of CHI and aids in the clinical management of these patients (24) . Before the advent of 18 F DOPA-PET CT, pancreatic venous sampling (PVS) and selective pancreatic arterial calcium stimulation with hepatic venous sampling (ASVS) were used to differentiate between the two subtypes (25, 26) . A recent systematic review and meta-analysis has found 18 F DOPA-PET CT to be far superior to PVS and ASVS in diagnosing and localising focal CHI (27) .
Patients with CHI associated with heterozygous paternally inherited ABCC8/KCNJ11 mutations may or may not have the second hit of somatic maternal allele loss in the pancreatic b-cell. Accordingly, these patients can either have focal or diffuse disease. Furthermore, diffuse disease can either be diazoxide-responsive or unresponsive depending on the underlying molecular basis of the mutation and other unclear genetic or environmental influences (28) . There are isolated case reports of heterozygous paternally inherited ABCC8/ KCNJ11 mutations leading to diffuse CHI in the literature (3, 10, 29, 30) . The proportion of patients with paternally inherited heterozygous ABCC8/KCNJ11 mutations who develop focal CHI has not been reported in any study so far. Herein, we describe the heterogeneous clinical presentation and the histological basis of a relatively large cohort of patients with heterozygous paternally inherited ABCC8/KCNJ11 mutations. We also report the proportion of focal and diffuse disease in a large cohort of CHI patients with paternally inherited heterozygous ABCC8/KCNJ11 mutations.
Subjects and methods
The study was approved by the Ethics Committee of Great Ormond Street Children's Hospital and the Institute of Child Health. Informed written consent was obtained from the parents of children enrolled for molecular genetic testing for CHI (ABCC8/KCNJ11 sequencing). This is a descriptive study of the clinical characteristics of children with CHI due to paternally inherited heterozygous ABCC8/KCNJ11 mutations. Clinical presentation, disease course and outcome for consecutive patients with CHI associated with paternally inherited heterozygous ABCC8/KCNJ11 mutations between the years 2000 and 2013 were retrospectively reviewed.
CHI was diagnosed by a controlled fasting test that demonstrated an inappropriately detectable serum insulin and/or C-peptide concentration and/or inappropriately low b-hydroxybutyrate and non-esterified fatty acids concentrations in the presence of hypoglycaemia (plasma glucose concentration !3.0 mmol/l). The patients with confirmed diagnosis of CHI underwent molecular genetic analysis after informed consent (see below). Diazoxide (5-15 mg/kg per day in three divided doses) was commenced as the first-line medical treatment. The patients were defined as diazoxide unresponsive if age appropriate fasting tolerance could not be achieved by treatment with 15 mg/kg per day diazoxide for a minimum of 5 days. Diazoxide-unresponsive patients associated with paternally inherited heterozygous ABCC8/KCNJ11 mutation underwent further investigations (PVS or diffuse disease. PVS was performed and interpreted as described previously by de Lonlay-Debeney et al. (26) . The detailed protocol used for 18 F DOPA-PET CT and analysis of the images has already been described (31) . Diazoxide-unresponsive diffuse disease was managed by octreotide injections (5-30 mg/kg per day in three to four divided doses)Gnear-total pancreatectomy along with carbohydrate-rich feeds. The focal disease was managed with the resection of the focal lesion or partial pancreatectomy. Post-surgery, glycaemic control was periodically assessed by 24-h blood glucose profile and controlled fast to ensure cure of the focal CHI and appropriate control of diffuse CHI.
Genetic testing
Genomic DNA was extracted from peripheral leukocytes using standard procedures. The single-coding exon of the KCNJ11 gene and the 39 exons of the ABCC8 gene were amplified using the PCR. Unidirectional sequencing was performed using universal M13 primers and a Big Dye Terminator Cycle Sequencing Kit v3.1 (Applied Biosystems) according to the manufacturer's instructions. The reactions were analysed on an ABI 3730 Capillary Sequencer (Applied Biosystems) and the sequences were compared with the reference sequences (NM_000525 and NM_000352.2) using Mutation Surveyor v3.24 (SoftGenetics, PA, USA). Dosage analyses by multiplex ligation-dependent probe amplification were done in patients with a heterozygous ABCC8/KCNJ11 mutation and diffuse disease on 18 F DOPA-PET scan/PVS (32).
LOH was investigated by microsatellite analysis of DNA extracted from paraffin-embedded pancreatic tissue and peripheral leukocytes, mainly when there was a discrepancy between the histology and 18 F DOPA-PET CT/PVS result. Six markers (D11S2071, D11S1964, D11S419, D11S1397, D11S1888 and D11S4138) spanning chromosome 11p15.1-11p15.5 were amplified by PCR and allele peak heights were compared using GeneMarker v1.85 (SoftGenetics).
Results
Over a period of 14 years (2000-2013), more than 300 children with confirmed biochemical and genetic diagnosis of CHI were managed in our centre. Of these, 53 children had paternally inherited heterozygous ABCC8/KCNJ11 mutation (ABCC8, 42 and KCNJ11, 11). Of the 35 different ABCC8 mutations seen in 42 patients, 19 affected a single amino acid (missense or in-frame deletion/insertion). Of the ten different KCNJ11 mutations seen in 11 patients, eight affected a single amino acid (missense or in-frame deletion/insertion), one was a frame shift mutation and one was a non-stop codon mutation resulting in extension of the Kir6.2 protein sequence by three amino acids ( 
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Clinical and biochemical characteristics
The mean (G2 S.D.) gestational age and birth weight of our cohort was 38.9 (G1.8) weeks and 3980 (G760) g respectively. Of these, 19 infants (36%) were macrosomic (birth weight O2 S.D.) at birth. The gender distribution was 37 males and 16 females. The majority of patients in our cohort were of Caucasian descent. Only one proband was a product of the consanguineous marriage. There were two pairs of two siblings and the rest of the cohort was unrelated. The median age of presentation with hypoglycaemia was !1 week (range !1-130 weeks). More than 85% (46/53) patients presented with hypoglycaemia within first week of life. The mean (GS.D.) serum insulin during hypoglycaemia was 21.1 (G34.2) mU/l. In three infants in whom serum insulin was undetectable, C-peptide level was inappropriately elevated for the blood glucose measurement. The serum ammonia was within normal range and b-hydroxybutyrate/non-esterified fatty acids were inappropriately low in all children (Table 1) .
Clinical course,
F DOPA-PET CT and PVS findings and final outcome
Diazoxide-responsive group " In two (4%) patients (Table 1 : patients 16 and 17), CHI resolved spontaneously within few weeks before investigations were repeated in our centre (Fig. 2) . Previous functional work has established milder disease phenotype with a mutation seen in one of these two patients (ABCC8 (E1507K)) (33) . The mutation identified in the second patient (ABCC8 (D1031N)) is not reported in dbSNP and predicted to be disease causing (Table 2) .
Sixteen patients (30%) with presumably diffuse CHI responded to diazoxide treatment (Fig. 2) . In three patients from diazoxide-responsive group who underwent 18 F DOPA-PET CT, diffuse uptake throughout the pancreas was noticed. Nine patients (17%) successfully managed to come off diazoxide treatment after a variable period of time. The remaining seven (13%) patients were on diazoxide for a median duration of 2.8 years (range 3 months-12 years) at the time of writing. The mutations in this subgroup are predicted to be pathogenic by various mutation prediction programmes (Table 2) (34, 35) .
Diazoxide-unresponsive group " The remaining 35 (66%) patients were unresponsive to maximum doses of diazoxide and were investigated either by using PVS (nZ8) or 18 F DOPA-PET CT scan (nZ27).
PVS was suggestive of diffuse disease in seven patients and no differentiation between focal and diffuse was CHI due to paternally inherited K ATP mutation (n=53) Figure 2 Clinical course, 18 F DOPA-PET CT/pancreatic venous sampling findings and outcome.
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The patient with indeterminate PVS underwent partial pancreatectomy and focal lesion was seen on the histology of the resected pancreas. Of the 27 patients who were investigated with 18 F DOPA-PET scan, focal uptake was seen in 21 and diffuse uptake in six patients (Fig. 3) . The focal lesion was successfully managed either with lesionectomy (nZ16) or partial pancreatectomy (nZ4). One patient was managed successfully with octreotide injections. The patients with diffuse tracer pancreatic uptake were either managed with near-total pancreatectomy (nZ3) or octreotide injections (nZ3). One patient from this subgroup had atypical histology with pancreatic b-cell enlargement in parts of body and head of the pancreas due to mosaic interstitial paternal uniparental isodisomy for chromosome 11p15.1 (36) .
Discussion
This study reports the proportion of focal disease in a large cohort of patients with CHI associated with paternally inherited heterozygous ABCC8/KCNJ11 mutations. In addition, it highlights the clinical and histological heterogeneity of CHI associated with paternally inherited heterozygous ABCC8/KCNJ11 mutation.
Mutations in the ABCC8/KCNJ11, which account for the majority of genetically confirmed CHI cases, can either be biallelic or monoallelic (3, 4, 37) . Biallelic ABCC8/KCNJ11 mutations result in diffuse CHI, whereas monoallelic mutations can either be asymptomatic (38) . In our cohort of 53 CHI patients associated with paternally inherited monoallelic ABCC8/KCNJ11 mutations, 18 (33%) patients either responded to diazoxide or resolved spontaneously and are likely to have dominant acting CHI. Mutations in these 18 patients are predicted to be pathogenic by different mutation prediction programmes (Table 2) . Functional work has already established some of these mutants to be dominant acting and exerting their effect by a dominant-negative mechanism (33, 39, 40) . Although there was no history of hypoglycaemia in the fathers of our cohort, formal evaluation with controlled provocation fasting studies has not been done. Other studies also have reported parents to be asymptomatic carriers of dominant acting mutations (41) . In view of severe diazoxide side effects and parental request, three patients from this subgroup underwent 18 F DOPA-PET CT imaging to avoid long-term treatment with diazoxide. This was in the hope that these patients could be managed with removal of focal lesion if found to be the underlying cause for CHI. However, as suspected from the phenotype of diazoxide-responsiveness, 18 In six (21%) diazoxide-unresponsive patients investigated with 18 F DOPA-PET CT, diffuse tracer uptake throughout the pancreas was noticed (Fig. 3) . Three of these patients were managed with near-total pancreatectomy and in one of these patients, histology and microsatellite analysis was suggestive of giant focal lesion (44) . Diffuse uptake in this particular patient was due to the size of the focal lesion, which occupied nearly the whole pancreas. Diffuse CHI has been described in the literature with paternally inherited ABCC8/KCNJ11 mutations. Fernandez-Marmiesse et al. (10) reported five patients with paternally inherited K ATP mutations and whose post pancreatectomy pathology result was not consistent with that of focal lesion. Similar findings have been reported by other studies (1, 21, 27, 30) . There are a number of possible mechanisms as to how a heterozygous ABCC8/KCNJ11 mutation can lead to diffuse disease. For example there could be a post-zygotic second hit within the pancreas or a maternally inherited mutation may reside within a non-coding regulatory/intronic region of the ABCC8/KCNJ11 gene. Recently, in a patient with focal CHI but no exonic or splice site ABCC8/KCNJ11 mutation, nextgeneration sequencing identified a deep intronic ABCC8 mutation inherited from the unaffected father, which created a cryptic spice site and an out of frame pseudoexon (32) . A third possibility is allelic drop-out due to a rare polymorphism within a primer binding site. In this scenario, a maternally inherited coding mutation could escape detection by Sanger sequencing. Besides, some of the missense mutations may be dominantly acting (dominant negative).
As compared with recessive acting mutations where there is defective biogenesis or trafficking of K ATP channel to the b-cell membrane, the dominant acting mutants traffic normally to the plasma membrane but show impaired responsiveness to the channel agonists, MgADP and diazoxide (45) . Diazoxide-unresponsive mutations produce a more severe impairment in the expressed channel response to activation by diazoxide and MgADP as compared with diazoxide-responsive mutations (28) .
A novel genetic mechanism of diffuse disease due to mosaic paternal uniparental isodisomy in a patient with heterozygous ABCC8/KCNJ11 mutations was recently described (36) . Lastly, it could also very rarely be due to failure of Sanger sequencing to detect the second ABCC8/KCNJ11 mutation or a missed histological diagnosis of focal CHI in these patients. Although ABCC8 and KCNJ11 are not known to be imprinted genes, they are next to the 11p15.5 imprinted region, so another hypothesis could be the involvement of epigenetic mechanisms.
In summary, of the 53 patients associated with paternally inherited ABCC8/KCNJ11 mutations, 29 (55%) patients had diffuse CHI (18 (34%) patients -diazoxideresponsive; 11 (21%) patients -diazoxide-unresponsive) and 24 (45%) patients had confirmed focal CHI either based on histology or LOH studies. One patient had giant focal lesion based on histology and LOH studies, confusing the interpretation of 18 F DOPA-PET CT.
From our results, it is clear that paternally inherited heterozygous ABCC8/KCNJ11 mutations can manifest as a wide spectrum of CHI with focal disease in 45% patients. This heterogeneous clinical picture could be due to modifying genes or other unknown factors, e.g. environmental, that influence the expression of the phenotype in CHI patients.
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